Corporate overview

Annexon Biosciences (Nasdaq: ANNX) is a late-stage clinical biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory aspects of classical complement pathway activation before it starts. As the only company solely focused on targeting C1q, Annexon is developing a fit-for-purpose pipeline of therapeutics designed to provide meaningful benefits across multiple complement-mediated diseases of the body, brain and eye.

Annexon is rigorously advancing global registrational programs for two candidates in Guillain-Barré syndrome and geographic atrophy, de-risked with proof-of-concept data in mid-stage clinical trials, to bring potential treatments to patients as quickly as possible.